A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

September 7, 2022

Study Completion Date

September 7, 2022

Conditions

Overweight and Obesity

Interventions

DRUG

NNC0174 0833

Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)

Trial Locations (1)

Novo Nordisk Investigational Site, Shanghai